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Drug binding to plasma proteins restricts their free and active concentrations, thereby aﬀecting their pharmacokinetic properties.
Species diﬀerences in plasma protein levels complicate the understanding of interspecies pharmacodynamic and toxicological
eﬀects. MBX-102 acid/JNJ39659100 is a novel PPAR-γ agonist in development for the treatment of type 2 diabetes. Studies were
performed to evaluate plasma protein binding to MBX-102 acid and evaluate species diﬀerences in free drug levels. Equilibrium
dialysis studies demonstrated that MBX-102 acid is highly bound (>98%) to human, rat and mouse albumin and that free MBX-
102 acid levels are higher in rodent than in human plasma. Interspecies diﬀerences in free drug levels were further studied
using PPAR-γ transactivation assays and a newly developed PPAR-γ corepressor displacement (biochemical) assay. PPAR-γ
transactivation and corepressor displacement by MBX-102 acid was higher in rat and mouse serum than human serum. These
results conﬁrm the relevance of interspecies diﬀerences in free MBX-102 acid levels.
Copyright © 2008 Holly J. Clarke et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
MBX-102/JNJ39659100 is a compound in development for
the treatment of type 2 diabetes. It is a single enantiomer
of halofenate, a drug that was tested clinically in the 1970s
as a hypolipidemic and hypouricemic agent [1–6]. Although
developed for lipid lowering, studies with halofenate in
diabetic patients also demonstrated signiﬁcant eﬀects on
plasma glucose and insulin both in monotherapy [7, 8]a n d
in combination with other oral hypoglycemic agents [9–11].
Two decades later, it was discovered that both halofenate and
MBX-102/JNJ39659100 are selective partial PPAR-γ agonists
[12, 13] thereby oﬀering an explanation for its antidiabetic
properties.
Translational medicine is important for studying the
action and safety of drugs. Studies in animals allow for
interventional procedures that are not appropriate for
humans. Key to interpreting these studies is to understand
the relationship of the pharmacologically active form, (i.e.,
free drug) to the pharmacodynamic eﬀects in each species
studied.
Connecting preclinical pharmacology and safety studies
in diﬀerent species to the likely human experience therefore
requires an understanding of the action of the drug at the
target from these diﬀerent species as well as the relationship
of the free, pharmacologically active form to total drug
concentration in these species.
For drugs with high serum protein binding this is
particularly important. High serum protein binding appears
to be a common feature of PPAR-γ agonists such as
rosiglitazone, pioglitazone, and others [14–16] and previous
data suggest that it may also be a feature of halofenate
[17, 18] and therefore, also of MBX-102/JNJ39659100.
Accurately determining free levels of highly plasma protein-
bound drugs is technically challenging, making comparisons
between species for these drugs extremely diﬃcult. In the
results reported herein, methods were used that allow for
comparison between mouse, rat, and human plasma protein
binding. This allowed for the appropriate interpretation of
the pharmacology and potential for human risk of MBX-
102/JNJ39659100. This study provides an approach that
could be applied to the translational medicine and safety
assessments for other PPAR agonists.2 PPAR Research
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Figure 1: Structure of rosiglitazone, pioglitazone, and MBX-102 acid (active form).
2. MATERIALS AND METHODS
[3H] MBX-102 acid (740 GBq/mmol, 20 Ci/mmol) was
synthesized by Amersham Biosciences (Buckinghamshire,
UK). MBX-102 acid was synthesized at IRIX Pharma-
ceuticals (Florence, SC, USA). The structure of MBX-
102 acid is shown in Figure 1 in comparison to the
full agonists, rosiglitazone and pioglitazone. For radio-
labeled binding studies, pooled frozen plasma from either
Sprague Dawley rats, CD-1 mice, or humans were purchased
from Bioreclamation, Inc. (Hicksville, NY, USA). For the
competitive equilibrium dialysis experiments, fresh pooled
mixed gender plasma from either CD-1 mouse, Sprague-
Dawley rat, or humans obtained from Bioreclamation,
Inc. (Hicksville, NY) were used. Human, mouse, and rat
serum albumins, and human alpha-1-acid glycoprotein were
purchased from Sigma (St. Louis, Mo, USA). Charcoal
stripped and delipidated sera from either human males, CD-
1 male mice, or Sprague Dawley male rats were purchased
from Biochemed (Winchester, Va, USA). FDG (Fluorescein
di-β-D-galactopyranoside) was purchased from Invitro-
gen (Carlsbad, Calif, USA). Lanthascreen TR-FRET PPAR-
gamma Coactivator Assay Kit and ﬂuorescently labeled
NCOR peptide (Fluor-DPASNLGLEDIIRKALMGSFDDK)
were purchased from Invitrogen (Carlsbad, Calif). Steady
Glo reagent was purchased from Promega (Madison, Wis,
USA). DMEM culture media, Lipofectamine, Optimem,
andPenicillin-StreptomycinwerepurchasedfromInvitrogen
(Carlsbad, Calif). Bovine Insulin, isobutylmethylxanthine,
and dexamethasone were purchased from Sigma (St. Louis,
Mo). HEK 293T cells were obtained from ATCC (Manassas,
Va, USA). Pro 293-Culture deﬁned media was purchased
from Cambrex (East Rutherford, NJ, USA).
2.1. Formulationof[3H]MBX-102acid
Radiolabeled MBX-102 acid was prepared as a 1mL ethanol
solution at a concentration of 50μM (1mCi total). Stock
MBX-102 acid dosing solutions (100-fold of ﬁnal con-
centration) were prepared with unlabeled MBX-102 acid
in dimethyl sulfoxide (DMSO) and spiked with 1μL/mL
(0.05μM) of [3H] labeled MBX-102 acid so that the ﬁnal
evaluated concentrations of MBX-102 acid were 400μM,
600μM, 1000μM, 1500μM, and 2000μM. Final solvent
concentrations were 1% of the total volume.
2.2. Determinationofplasmaproteinbindingof
MBX-102acidbyequilibriumdialysis
Plasma was stored at −20◦C. Prior to use, it was thawed and
spun at approximately 2000rpm for 5 minutes to remove
any precipitated material. The pH was adjusted to pH 7.4
by careful addition of NaH2PO4. A 1mL sample of spiked
plasma was prepared by direct dilution of [3H]-MBX-102
acid stock solution into plasma and then added to one side
of an equilibrium dialysis chamber. The other chamber was
ﬁlled with 1mL of 0.01M phosphate buﬀered saline (PBS).
The dialysis apparatus was placed in a water bath at 37◦CHolly J. Clarke et al. 3
Table 1: Binding of MBX-102 acid to rat, mouse, and human plasma determined by equilibrium dialysis. Binding of [3H] MBX-102 acid
to plasma was conducted by equilibrium dialysis against PBS buﬀer at 37◦C and the percentage of total radiolabel bound to plasma was
determined by dividing the amount of sample in the plasma compartment by the combined total amounts in the plasma and PBS buﬀer
compartments. Values represent the result of a representative experiment and are the mean ± SD of triplicate determinations.
MBX-102 acid (μM) %Protein Binding ± SD
Human Mouse Rat
400 99.8 ±0.19 9 .8 ±0.09 9 .8 ±0.1
600 99.8 ±0.19 9 .7 ±0.09 9 .8 ±0.1
1000 99.7 ±0.19 9 .5 ±0.19 9 .7 ±0.0
1500 100 ± 0.1 99.8 ±0.19 9 .8 ±0.2
2000 99.8 ±0.19 9 .5 ±0.19 9 .5 ±0.1
and rotated at 20rpm. Preliminary studies indicated that
equilibrium is achieved within 5 hours (data not shown).
Once equilibrium was established, the contents of the cell
chambers were removed and analyzed by liquid scintillation
counting. The chambers were sampled in triplicate. Nonspe-
ciﬁc binding, in the absence of plasma, was determined to be
5.3 +/− 3.9% (mean +/− SD, n = 3). The mean recovery of
[3H]MBX-102acidwasdeterminedintriplicatebysampling
of both dialysis chambers at each concentration of MBX-
102 acid. The recovery percentage was found not to vary
with MBX-102 acid concentration. The mean +/− SD %
recoveries across all MBX-102 acid concentrations for each
s p e c i e sw e r e8 3 . 9+ / − 6.7%, 84.4 +/− 2.4%, and 85.8 +/−
2.6% for human, rat, and mouse plasma, respectively.
2.3. DeterminationofproteinbindingofMBX-102acid
toselectedhumanplasmaproteins
Stock solutions of human serum albumin and alpha-1-acid
glycoprotein were prepared in PBS buﬀer. Human serum
albumin (40mg/mL, ∼600μM) and human alpha-1-acid
glycoprotein (22.5μM) were spiked with [3H] MBX-102
acid. The spiked protein solution (175μL) was added to one
sideofanequilibriumdialysischamber,andanequalvolume
of PBS buﬀer was added to the other chamber. Dialysis was
allowed to reach equilibrium and the binding to protein was
determined by liquid scintillation counting of samples from
both chambers as described above. The percent recovery of
[3H] MBX-102 acid with both serum proteins was between
95.7% and 98.5%.
2.4. DeterminationofMBX-102acidbindingto
albuminbysurfaceplasmonresonance(SPR)
The characterization of the binding of MBX-102 acid against
human, mouse, and rat albumin was performed using SPR-
based biosensors (Biosensor Tools, Salt Lake City, Utah,
USA). The assay methods used to assess the binding of
MBX-102 acid to human, mouse, and rat albumins have
been described previously [19]. Brieﬂy, each albumin was
immobilized onto a CM5 sensor chip using standard amine
coupling. Immobilization densities were between 10000 and
13000 RU. The test compound was run in a twofold dilution
series with the highest concentration of 200μM. Each of
the 16 diﬀerent concentrations was tested in duplicate.
The running buﬀer contained 53mM Na2HPO4, 12.5mM
KH2PO4,7 0 m MN a C la tp H7 . 4 ,a n d5 %D M S O .A l l
binding data were collected at 37◦C. The binding response
proﬁle of MBX-102 acid over the three diﬀerent albumin
surfaces was evaluated and the binding constants for the
high-aﬃnity site were determined using a two-independent-
site model. Conversion from KD to %bound was performed
as previously described [19].
2.5. Determinationofspeciesdifferencesin
proteinbindingofMBX-102acidbycompetitive
equilibriumdialysis
Acomparisonofthebindingtoplasmafromdiﬀerentspecies
was performed essentially by the method described below.
Brieﬂy, [3H] MBX-102 acid spiked plasma samples were
formulated as described above with the exception that pH
was not adjusted to 7.4 and the ﬁnal DMSO concentration
was 0.6%. A 1mL sample of spiked human plasma was
applied to one side of the dialysis membrane and 1mL
of spiked animal plasma was applied to the other side.
The samples were dialyzed by rotation at 20rpm for up to
120 hours in a 37◦C incubator. The ratio of free drug in
plasma was calculated according to the equation: ratio of
free drug (animal versus human) = (total cpm in human
plasma)/(total cpm in animal plasma).
2.6. Cellculture
HEK 293T cells (ATCC) were cultured in 15-cm dishes
at subconﬂuence (approx. cell density was 14000/cm2)i n
DMEM (high glucose), and 10% (v/v) fetal bovine serum
(FBS) supplemented with 1% (v/v) Penicillin-Streptomycin.
Allcellsweremaintainedat37◦Cinahumidiﬁedatmosphere
of 8% CO2 in air.
2.7. PPAR-γ reportergeneassays
HEK-293T cells were cultured as described above. Prior to
use, the cells were trypsinized using 0.25% trypsin/1 mM
EDTA and resuspended in DMEM, 10% (v/v) FBS lacking
Penicillin-Streptomycin. For a pool suﬃcient to supply 100
wells, 6 million cells were diluted into medium for a total4 PPAR Research
volume of 9mL. The DNA-Lipofectamine 2000 mixture was
prepared as per manufacturer’s instructions. For a pool
suﬃcienttosupply100wells,5μgGal4-M ousePP AR -γ LBD,
5μg pFR-Luciferase, and 500ng Lac-z plasmids were mixed
with 40μL of Lipofectamine 2000 in Optimem medium
in a total volume of 1mL. The cell suspension was mixed
with 1mL of the DNA-Lipofectamine 2000 mixture. The
mixture was plated into a 96-well plate and incubated for 4
hours at which time the transfection medium was removed
and replaced with 100μL DMEM, 10% (v/v) FBS and
cultured overnight. The culture medium was then removed
from the plates and replaced with 50μL Pro293A medium.
Compounds and charcoal stripped/delipidated serum or
serum albumin, or alpha-1 acid glycoprotein stock solutions
were prepared at 2X ﬁnal concentration in Pro293A medium
and mixed together prior to addition of 50μL to the
transfected cells and incubated for an additional 24 hours.
Measurement of luciferase and ﬂuorescence activity was per-
formed according to the manufacturer’s instructions. Brieﬂy,
after removal of media, cells were incubated for 10 minutes
in 100μLo fS t e a d y - G l or e a g e n t .A n8 0μL lysate aliquot was
transferred to opaque white well plates and the luminescence
measured. The 80μL aliquot was then transferred back to
the original plate. The ﬂuorescence emission (excitation
485nm, emission 535nm) was measured after the addition
of 100μLo f1 0 μM ﬂuorescein di-β-D-galactopyranoside
in assay buﬀer (2.1mM KH2PO4, 310.3mM NaCl, 5.9mM
Na2HPO4-7H2O, 20mM KCl, 2mM MgSO4,0 . 2 %t r i t o n -
X100). Each experimental condition was assessed in qua-
druplicate. The data were normalized for each well by
dividing the luminescence measurement by the ﬂuorescence
measurement. Dose-response curves were generated and
EC50 values were calculated using Prism Graphpad version
5.1.
2.8. Lanthascreencorepressordisplacementassay
Assays were performed according to the manufacturer’s
instructions. Brieﬂy, GST-PPARγ-LBD (5nM), Tb-labeled
anti-GST antibody (5nM), and ﬂuorescent-peptide
(125nM) were diluted together in kit assay buﬀer with
5mMDTTand10μL/well of this solution was added to 384-
well black plates (Costar, Corning Inc. Life Science, Lowell,
Mass, USA). Ligands were prepared as stock solutions in
DMSO at 100-fold their ﬁnal concentration followed by
dilution to 2X concentration in kit assay buﬀer with 5mM
DTT containing a 2X concentration of serum albumin or
charcoal stripped/delipidated serum prior to addition of
10μL/well to the assay plate. The plate was covered and
incubated for 4 hours at room temperature. The time
resolved ﬂuorescence resonance energy transfer (TR-FRET)
signal was measured using a Pherastar ﬂuorescence counter
(BMG labtech, Oﬀenburg, Germany). The ratio of the
emission intensity of the acceptor (Fluorescein: λ = 520nm)
divided by the emission intensity of the donor (Tb: λ =
490nm) was then calculated to determine the degree of
NCOR binding. Each measurement was performed in
quadruplicate. Dose-response curves were generated and
Table 2: Binding of MBX-102 acid to rat, mouse, and human
albumin determined by plasmon resonance-based biosensors. The
binding constants for the high-aﬃnity site were determined at
37◦C. Values represent the mean of duplicate determinations (HSA:
human serum albumin, MSA: mouse serum albumin, RSA: rat
serum albumin).
Interaction KD (μM) %Bound
HSA:MBX-102 5.8 99.1
MSA:MBX-102 5.5 99.2
RSA:MBX-102 12.8 98.1
IC50 values were calculated using Prism Graphpad version
5.01.
2.9. Statistics
To compare logEC50 (or logIC50), ANOVA model of ran-
domized block design was used. If block eﬀect (experiment
eﬀect) was not signiﬁcant, the data were reanalyzed by a
reduced ANOVA model. Tukey’s test was used for multiple
comparisons (SAS). Diﬀerences were considered signiﬁcant
at a P value <.05.
3. RESULTS
3.1. InterspeciesproteinbindingofMBX-102acid
MBX-102 is a selective partial PPAR-γ modulator which is
structurally distinct from the full PPAR-γ agonists, rosiglita-
zone and pioglitazone (see Figure 1). In order to understand
the relationship between free drug levels and the eﬃcacy
of the selective partial PPAR-γ agonist MBX-102 acid in
diﬀerent species, the plasma binding properties of MBX-102
acid were determined. Pooled, mixed sex plasma obtained
from humans, Sprague Dawley rats, and CD-1 mice were
spiked with MBX-102 acid and the % MBX-102 acid bound
to protein was determined by equilibrium dialysis. The data
shown in Table 1 reveal that MBX-102 acid is 99.5%–100%
bound to plasma proteins from humans, rats, and mice. The
high degree of binding observed was also independent of
MBX-102acidconcentration.ToidentifypotentialMBX-102
acid binding proteins in humans, equilibrium binding stud-
ies were performed using puriﬁed human serum albumin
and human alpha 1-acid glycoprotein. A high level of MBX-
102 acid binding (>98%) to human serum albumin was
observed. In comparison, the binding to human alpha 1-acid
glycoprotein was very low (<5%) (data not shown). These
studies indicate that the selective partial PPAR-γ agonist
MBX-102 acid is highly protein-bound in plasma across
diﬀerent species and identiﬁes serum albumin as a protein
that binds MBX-102 acid.
To further characterize the binding of MBX-102 acid to
albumin, we used surface plasmon resonance (SPR), a label-
free technique that can be used to provide information on
the kinetics and aﬃnity of complex formation for drugs that
are highly bound to albumin [19, 20]. The binding constants
(KD) and the bound percentage for human, mouse, and
rat albumin are reported in Table 2.I nf u l la g r e e m e n tHolly J. Clarke et al. 5
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Figure 2: PPAR-γ activation by (a) MBX-102 acid, (b) rosiglitazone, and (c) pioglitazone in the presence of increasing human serum.
Normalized reporter assay data were calculated as the percentage of maximum signal by expressing each data point as a percentage of
the mean for the maximum signal. The percentage of maximum signal for the curves representing 0%, 2%, 10%, and 20% (v/v) serum was
calculated independently. The dose-response curves shown are from a representative experiment. Values are EC50 (μM) determined from 3
experiments and shown as the mean ± SD.
with the studies reported above, MBX-102 acid binding to
albumin was >98%. This high degree of protein binding
precluded any further analysis of diﬀerential binding of
MBX-102 acid to plasma proteins across species because
the absolute binding could not be determined accurately by
any of the two methodologies used. Therefore, competitive
equilibrium dialysis (CED) was used to address the question
of diﬀerences in the binding of MBX-102 acid to plasma
proteins among species. CED utilizes competition dialysis
between the plasma of two species to accurately determine
the ratios of the free drug fractions in these species [21].
Usingthistechnique,theratioofthefreefractionsisinversely
related to the fold accumulation of total drug in the plasma
of each species plasma at equilibrium. The ratios of rat-to-
human and mouse-to-human free fraction were determined
over several concentrations of MBX-102 acid. The data
shown in Table 3 indicate that the free MBX-102 acid in rat
plasma is 1.7 to 2.3 fold higher than in human plasma and6 PPAR Research
Table 3: Interspecies free MBX-102 acid ratios determined by
competitive equilibrium dialysis.[ 3H] MBX-102 acid distribution
between either mouse and human plasma or rat and human plasma
was conducted by competitive equilibrium dialysis at 37◦C. Values
represent mean ± SD for 5 independent experiments.
MBX-102 Acid (μM) Free Fraction Ratio (n = 5 ±SD)
Rat:Human Mouse:Human
100 2.3 ±0.61 0 .5 ±5.5
300 2.3 ±0.65 .9 ±3.6
700 2.0 ±0.33 .7 ±1.9
1000 1.8 ±0.22 .6 ±1.1
1300 1.7 ±0.22 .3 ±0.7
thatthefreeMBX-102acidconcentrationinmouseplasmais
2.3 to 10.5 fold higher than in human plasma. Interestingly,
both the rat-to-human and the mouse-to-human free drug
ratios were found to decrease with total drug concentration
possibly due to saturation of weak binding sites on human
binding proteins. These ﬁndings predict that at a ﬁxed total
drug level of MBX-102 acid, the relative free drug levels
across species will be in the order mouse > rat > human.
3.2. ActivationofPPAR-γ byfreedrugin
thepresenceofhumanserum
The ﬁnding that the partial PPAR-γ agonist MBX-102 acid
is diﬀerentially bound to plasma proteins across species
suggested that the free levels, putatively responsible for
pharmacodynamic eﬀects of MBX-102 acid, could lead to
ad i ﬀerent dependence on total drug levels amongst the
diﬀerent species. In order to fully interpret the impact of
diﬀerent levels of free MBX-102 acid between species, it
is essential to conﬁrm that free drug level is responsible
for the action at the receptor and to know if there are
any intrinsic interspecies diﬀerences in PPAR-γ activity of
MBX-102 acid. PPAR-γ reporter gene assays demonstrated
that there were no intrinsic diﬀerences in the ability of
MBX-102 acid to activate human, mouse, or rat PPAR-γ
(data not shown). To understand the eﬀect of serum on
the activation of PPAR-γ by MBX-102 acid, the ability of
MBX-102 acid to transactivate PPAR-γ was determined in a
cell-based assay in the presence of increasing concentrations
of human serum. As illustrated in Figure 2(a), MBX-102
acid induced PPAR-γ activity in a dose-dependent manner
in the absence of serum. In the presence of increasing
concentrations of human serum, there was a pronounced
and serum concentration-dependent rightward shift of the
dose-response curve for MBX-102 acid. The fold changes in
mean EC50 values relative to no serum were 3, 19-, and 29-
fold for 2%, 10%, and 20% human serum, respectively. At
higher human serum concentrations, there was a decrease
in the window of activation precluding an analysis of serum
concentrations above 20%. Similar studies were performed
for the full PPAR-γ agonists, rosiglitazone and pioglitazone
(see Figures 2(b) and 2(c)). For both compounds, as was
seen for MBX-102 acid, a rightward shift in the dose-
response curve for PPAR-γ activation was observed in the
presence of 10% human serum compared to serum free. For
rosiglitazone, there was a 14-fold increase in EC50,a n df o r
pioglitazone, there was an 8-fold increase in EC50.S e r u m
protein binding therefore aﬀects the degree to which PPAR-
γ can be activated by agonists in a cellular environment.
Similar studies were performed for all three PPAR-γ agonists
in the presence of human serum albumin. As expected, the
EC50s for activation of PPAR-γ were rightward shifted in
the presence of human serum albumin for all three PPAR-γ
agonists (see Figures 3(a), 3(b),a n d3(c)). Concentrations of
serumalbumingreaterthan0.08%causedinterferenceinthe
reporter assay precluding an analysis of the eﬀect of higher
and more physiologically relevant albumin concentrations.
To further conﬁrm the selectivity of the albumin eﬀect, the
EC50 for activation of PPAR-γ was also evaluated in the
presenceofalpha1-acidglycoprotein.Asanticipated,noshift
in EC50 was detected even in the presence of the highest
concentration of alpha 1-acid glycoprotein tested (0.14%,
data not shown).
3.3. DifferentialactivationofPPAR-γ acrossspecies
OnthebasisoftheﬁndingthatMBX-102acidisdiﬀerentially
bound to serum proteins from human, mouse, and rat,
and the conﬁrmation that free drug levels determine the
ability of MBX-102 acid to activate PPAR-γ, it is predicted
that MBX-102 acid should diﬀerentially activate PPAR-
γ in the presence of serum from diﬀerent species. As
illustrated in Figure 4, this was found to be the case. In the
presence of 10% human, rat, or mouse serum, MBX-102
acid activated PPAR-γ with EC50s of 260μM, 196μM, and
170μM, respectively. These diﬀerences in EC50 were found
to be highly statistically signiﬁcant. Similar studies were
also performed with the full PPAR-γ agonists, rosiglitazone
and pioglitazone. As summarized in Table 4, MBX-102 acid
activation of PPAR-γ was aﬀected diﬀerently in the presence
of 10% serum from diﬀerent species compared to the eﬀects
seen with rosiglitazone and pioglitazone. For MBX-102 acid,
the EC50 in the presence of mouse and rat serum occurred
at lower concentrations than in human serum, whereas for
both rosiglitazone and pioglitazone the opposite eﬀect was
observed, namely, that higher concentrations were needed
in the presence of rat and mouse serum. These data suggest
that the diﬀerential eﬀect of serum on PPAR-γ activation
observed with MBX-102 acid is a property of MBX-102 acid
and not of the serum proteins.
3.4. Differentialcorepressordisplacementfrom
PPAR-γ acrossspecies
The cell-based PPAR-γ reporter assay is adversely aﬀected by
mouse serum concentrations greater than 10% precluding
analysis of cross-species diﬀerential serum binding at serum
concentrations closer to physiological levels. An alternate
in vitro assay was developed that allowed the assessment
of the eﬀect of much higher and more physiologically
relevant serum concentrations on MBX-102 acid action.
The data shown in Figure 5 demonstrate that a peptideHolly J. Clarke et al. 7
Table 4: Diﬀerential activation of PPAR-γ by PPAR-γ agonists in the presence of 10% of human, rat, and mouse serum. Values are EC50 (μM)
determined from 3 experiments and shown as the mean ± SD. FC is the ratio of EC50s for human: rat or human: mouse (∗ = P<. 05, ∗∗ =
P<. 01, ∗∗∗ = P<. 001 by ANOVA with Tukey post hoc test).
PPAR agonist Mean EC50 (μM) ±SD Fold Change in EC50
Human Rat Mouse Human:Rat Human:Mouse
MBX-102 acid 260 ± 16.9 196 ± 18 169 ± 5.2 1.33∗∗ 1.53∗∗∗
Rosiglitazone 2.0 ±0.15 .2 ±0.34 .5 ±0.30 . 3 9 ∗∗∗ 0.45∗∗∗
Pioglitazone 8.3 ±0.41 1 .4 ±1.29 .7 ±1.40 . 7 3 NS 0.86NS
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Figure 3: PPAR-γ activation by (a) MBX-102 acid, (b) rosiglitazone, and (c) pioglitazone in the presence of increasing human serum albumin.
Normalized reporter assay data were calculated as the percentage of maximum signal as described in Figure 2. The percentage of maximum
signal for the curves representing 0 and 0.08% serum albumin was calculated independently. The dose-response curves shown are from a
representative experiment. Values are EC50 (μM) determined from 2–6 experiments and shown as the mean ± SD.8 PPAR Research
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Figure 4: Activation of PPAR-γ by MBX-102 acid in the presence
of human serum compared to mouse and rat serum. Normalized
reporter assay data are expressed as the percentage of maximum
signal as described in Figure 2. The dose-response curves shown
are from representative experiments. MBX-102 acid activation of
PPAR-γ in the presence of 10% (v/v) human (H), mouse (M),
or rat (R) serum. The dose-response curves shown are from a
representative experiment. Values are EC50 (μM) determined from
3 experiments and shown as the mean ±SD. FC is the ratio of EC50s
for human: rat or human: mouse (∗ = P<. 05, ∗∗ = P<. 01, ∗∗∗
= P<. 001 by ANOVA with Tukey post hoc test).
derived from the corepressor NCOR is constitutively bound
to the ligand-binding domain of PPAR-γ and can be fully
displacedbyMBX-102acidwithanIC50 of11μM.Increasing
concentrations of human serum caused a rightward shift of
the dose-response curve resulting in up to a 19-fold shift
in the IC50 at 40% human serum. Diﬀerential displacement
of NCOR by MBX-102 acid was assessed at 40% serum for
human, rat, and mouse (see Figure 6). The fold changes in
IC50 for human-to-rat serum and human-to-mouse serum
were 4 and 7, respectively. These data are very consistent
with the relative free drug ratios predicted by the competitive
equilibrium dialysis studies.
4. DISCUSSION
The data presented here demonstrate that MBX-
102/JNJ39659100 is highly protein-bound, as had been
suggested by previous studies with halofenate, and that at
least one of the MBX-102 acid binding proteins is serum
albumin. Our goal was to understand the serum binding
properties of MBX-102 acid across species and to use this
information in interpreting the pharmacodynamic and
toxicological eﬀects across species. The use of competitive
equilibrium dialysis studies successfully demonstrated that
MBX-102 acid is indeed diﬀerentially bound to plasma
with the order of tightness of binding being human >
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Figure 5: Displacement of NCOR corepressor peptide from PPAR-
γ by MBX-102 acid in the presence of human serum. MBX-102
acid induced displacement of NCOR corepressor peptide from
the human PPAR-γ ligand-binding domain in the presence of
human serum at 0, 10%, or 40% (v/v). Normalized FRET assay
data are expressed as the percentage of maximum signal (as
described in Figure 2). The dose-response curves shown are from
a representative experiment. Values are IC50 (μM) determined from
3 experiments and shown as the mean ± SD.
rat > mouse. The studies performed using the cell-based
PPAR-γ reporter assay conﬁrmed, at least qualitatively, our
hypothesis that the pharmacodynamic eﬀects of MBX-102
acid are dictated by free drug levels and, further, that the
diﬀerential binding of MBX-102 acid to serum proteins
across species also results in a predictable and highly
reproducible eﬀect on pharmacodynamics. From these
studies, the order of binding of MBX-102 acid to serum
a c r o s ss p e c i e si sp r e d i c t e dt ob eh u m a n> rat > mouse,
which is in agreement with the data from the CED studies.
Although we observed good qualitative correlations with
the reporter assay and the CED assay, the magnitude of
shifts in EC50 in the reporter assay was much smaller than
those seen with the CED assay. One limitation of these
reporter assay studies was the inability to investigate the
eﬀect of serum concentrations higher than 10% which
could possibly explain the quantitative diﬀerences observed
between these two assays. For this reason, we developed a
new assay for measuring PPAR-γ activity in vitro that was
able to tolerate serum concentrations as high as 40%. The
data from this new assay conﬁrmed the predicted order of
binding for MBX-102 acid to serum across species as human
> rat > mouse and also provided quantitatively very similar
fold changes to the CED assay. The basis of the diﬀerential
binding of MBX-102 to serum albumin from diﬀerent
species is unknown. Although at the protein level, mouse
and rat albumins are highly conserved (∼90% homology),Holly J. Clarke et al. 9
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Figure 6: Displacement of NCOR corepressor peptide from PPAR-γ
ligand-binding domain by MBX-102 acid in the presence of human
serum compared to mouse and rat serum. MBX-102 acid induced
displacement of NCOR corepressor peptide from human PPAR-γ
ligand-binding domain in the presence of 40% (v/v) human (H),
mouse (M), or rat (R) serum. Normalized FRET assay data are
expressed as the percentage of maximum signal (“percentage of
maximal signal,” as described in Figure 2(a)). The dose-response
curves shown are from a representative experiment. Values are IC50
(μM) determined from 3 experiments and shown as the mean ±
SD. FC is the IC50 fold change of mouse or rat compared to human
(∗∗∗ = P<. 001 by ANOVA with Tukey post hoc test).
the degree of conservation is much lower between human
and mouse (∼72%) and human and rat (∼73%). Such
diﬀerences may, at least in part, be responsible for the
diﬀerential binding observed between species.
The approaches described here will be generally useful
for interpreting preclinical pharmacology data in diﬀerent
species as well as toxicology studies and how these will relate
to the human experience. Whilst conﬁned initially to PPAR-
γ, the approaches could easily be adapted for PPAR-α and
PPAR-δ and indeed to virtually any other ligand-modulated
receptor.
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